Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.68−0.07 (-8.81%)
Close on Nov 12, 2026Market cap $22.22MP/E –Yield –
Celularity gross margin
Gross margin is gross profit as a percentage of revenue.
Celularity's gross margin for the twelve months ending Jun 30, 2026 was 19.2%. For fiscal 2025 it was 24.4%, against 72.4% the year before. The highest annual figure on record is 72.4% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.4% | −48.0 |
| FY2024 | Dec 31, 2024 | 72.4% | +42.7 |
| FY2023 | Dec 31, 2023 | 29.7% | +39.1 |
| FY2022 | Dec 31, 2022 | -9.4% | −64.2 |
| FY2021 | Dec 31, 2021 | 54.8% | −10.7 |
| FY2020 | Dec 31, 2020 | 65.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 56.8% | +48.2 |
| Q1 FY2026 | Mar 31, 2026 | 62.2% | −6.6 |
| Q4 FY2025 | Dec 31, 2025 | -79.7% | −139.2 |
| Q3 FY2025 | Sep 30, 2025 | 26.1% | −32.1 |
| Q2 FY2025 | Jun 30, 2025 | 8.6% | −73.9 |
| Q1 FY2025 | Mar 31, 2025 | 68.9% | −19.9 |
| Q4 FY2024 | Dec 31, 2024 | 59.5% | +38.8 |
| Q3 FY2024 | Sep 30, 2024 | 58.2% | +53.4 |
| Q2 FY2024 | Jun 30, 2024 | 82.5% | +9.8 |
| Q1 FY2024 | Mar 31, 2024 | 88.8% | +39.7 |
| Q4 FY2023 | Dec 31, 2023 | 20.7% | +47.7 |
| Q3 FY2023 | Sep 30, 2023 | 4.9% | +79.3 |
| Q2 FY2023 | Jun 30, 2023 | 72.7% | +56.9 |
| Q1 FY2023 | Mar 31, 2023 | 49.1% | +16.9 |
| Q4 FY2022 | Dec 31, 2022 | -27.1% | −31.1 |
| Q3 FY2022 | Sep 30, 2022 | -74.4% | −152.7 |
| Q2 FY2022 | Jun 30, 2022 | 15.8% | −39.1 |
| Q1 FY2022 | Mar 31, 2022 | 32.2% | −21.1 |
| Q4 FY2021 | Dec 31, 2021 | 4.0% | −59.9 |
| Q3 FY2021 | Sep 30, 2021 | 78.2% | +9.0 |
| Q2 FY2021 | Jun 30, 2021 | 55.0% | – |
| Q1 FY2021 | Mar 31, 2021 | 53.3% | – |
| Q4 FY2020 | Dec 31, 2020 | 63.9% | – |
| Q3 FY2020 | Sep 30, 2020 | 69.2% | – |
See a number that looks wrong?